VivoSeq
Other

Cerebral Infarction

32

Pipeline Programs↗

2

Active Trials↗

21

Companies Involved↗

Cerebral Infarction is a moderately active landscape with 32 programs across 21 companies. The most active players are Merck & Co., CHABiotech CO., Ltd, Akero Therapeutics. 10 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

15/100

Mech. Concentration

10/100

Completion Rate

81/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2C

CHABiotech CO., Ltd

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2A

Asia Cell Therapeutics (Shanghai) Co., Ltd.

1 program

Phase 2S

Sclnow Biotechnology Co., Ltd.

2 programs

Phase 2Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

39 of 43 classified programs — the dominant modality here.

9%ALL OTHERSProtein / enzyme25%Cell therapy25%

Small molecule leads; the ring shows all 43 classified programs, each share of the total. Modality classified for 100% of 45 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed13 · 45%
Unknown status11 · 38%
Suspended2 · 7%
Recruiting1 · 3%
Not yet recruiting1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

29 trials

Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
Recruiting·—·N/A·NCT07305922·200 enrolled
CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN
Not yet recruiting·YYonsei University·Phase 3·NCT06770426·40 enrolled
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 3·NCT00129805·1,510 enrolled
Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00684515·90 enrolled
Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase
Completed·XXuanwuH 2·Phase 2·NCT02259738·120 enrolled
Which Factors Influence the Duration and the Success of Mechanical Thrombectomy During the Acute Phase of Cerebral Infarction?
Completed·—·N/A·NCT03451903·106 enrolled
Neuroprotective Effects of Xenon Treatment in Patients with Cerebral Infarction
Completed·NNegovsky Reanimatology Research Institute·Phase 3·NCT05335109·40 enrolled
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
Completed·Sanofi logoSanofi·Phase 4·NCT00386191·1,110 enrolled
Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.
Completed·Otsuka logoOtsuka·Phase 3·NCT00766545·1,095 enrolled
Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
Completed·Takeda logoTakeda·N/A·NCT02181842·246 enrolled
Neuroprotection Impact of Cyclosporin A in Cerebral Infarction
Completed·HHospices Civils de Lyon·Phase 2·NCT01527240·126 enrolled
Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject
Completed·Otsuka logoOtsuka·Phase 4·NCT00823875·200 enrolled
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01273467·13 enrolled
Nimodipine for Treating Acute Massive Cerebral Infarction
Completed·FFengtian Hospital·Phase 4·NCT02248233·72 enrolled
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
Completed·CCHABiotech CO., Ltd·Phase 1/2·NCT02378974·18 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)